

Beclomethasone dipropionate aerosol in allergic rhinitis

D.W. COCKCROFT,* MD, B SC; D.W. MACCORMACK; M.T. NEWHOUSE, MD, M SC, FRCP[C];
F.E. HARGREAVE, MD, MRCP

Treatment with beclomethasone dipropionate aerosol (BDA), 50 µg four times daily in each nostril, was compared with placebo therapy in a double-blind non-crossover trial of 30 matched patients with allergic rhinitis induced by ragweed pollen. The trial was started at the beginning of the ragweed season and continued for 42 days. Response to treatment was assessed from information on daily diary cards, weekly objective measurements of nasal patency and measurement of total eosinophil count (TEC) before treatment and at week 4. Patients in the BDA group had significantly less ($P < 0.05$) sneezing, rhinorrhea and nasal stuffiness at 36 days, cough at 10 days and antihistamine consumption at 17 days. There was no significant difference between the groups in eye symptoms, nasal airway inspiratory resistance, maximum inspiratory nasal flow or TEC. Overall comparison with previous pollen seasons by the patients indicated moderate to great improvement in 86% of the BDA group and in 13% of the placebo group ($P < 0.01$). Minor side effects were noted by two patients in each group.

Le traitement au dipropionate de béclo méthasone en aérosol (DBA), à raison de 50 µg dans chaque narine quatre fois par jour, a été comparé au traitement à un placebo dans une étude à double insu, sans chassé-croisé, chez 30 patients appariés souffrant de rhinite allergique provoquée par le pollen de jacobée. L'essai a débuté au commencement de la saison des jacobées et s'est poursuivi pendant 42 jours. La réponse au traitement a été évaluée à partir de l'information recueillie sur des agendas, les mesures objectives hebdomadaires de l'ouverture nasale et le compte des éosinophiles totaux (CET) avant le traitement et après 4 semaines. Les patients dans le groupe DBA ont eu significativement moins ($P < 0.05$) d'éternuements de rhinorrhée et de congestion nasale après 36 jours, de toux après 10 jours et de consommation d'antihistaminiques

après 17 jours. On n'a constaté aucune différence significative entre les deux groupes en ce qui a trait aux symptômes oculaires, à la résistance nasale inspiratoire, au débit inspiratoire nasal maximum ou au CET. La comparaison globale par les patients avec les saisons de pollen antérieures a indiqué une amélioration moyenne à grande chez 86% des sujets du groupe DBA et chez 13% du groupe placebo ($P < 0.01$). Des effets secondaires mineurs ont été observés chez deux patients de chaque groupe.

Allergic rhinitis is a common, troublesome condition. In the past, therapy has been based on environmental control, antihistamines, α -sympathetic stimulants, sodium cromoglycate and allergen injection. In spite of these measures symptoms may occur that require therapy with corticosteroids. Attempts to avoid the systemic side effects of corticosteroids have been made by using topical hydrocortisone,¹ prednisolone² and dexamethasone.³ Although these agents control the rhinitis they still result in substantial adrenal suppression.^{4,5} Recently two other corticosteroids, betamethasone-17-valerate^{6,7} and beclomethasone dipropionate,⁸⁻¹¹ which have potent local effects when used in small doses, have been introduced. Trials have shown these to be effective topically in controlling allergic rhinitis with no adrenal suppression.⁶⁻¹¹ However, in all these trials improvement was assessed by subjective methods (symptom scores, pill counts and observation of the nose). Objective assessment of nasal patency can be obtained by measuring nasal resistance^{12,13} and maximum inspiratory nasal flow (MINF).^{14,15}

We have carried out a double-blind non-crossover trial of therapy with beclomethasone dipropionate aerosol

(BDA) in 30 matched subjects with ragweed-pollen-induced rhinitis. Improvement was assessed both subjectively and objectively.

Patients and methods

Patients

Thirty patients with troublesome symptoms of allergic rhinitis in the ragweed pollen season were selected from the chest-allergy clinics of St. Joseph's Hospital and McMaster University Medical Centre. All gave a positive early response on prick skin-testing with ragweed pollen extract and a negative response to extracts of *Alternaria* and *Hormodendrum*, fungal spores present in the atmosphere concurrently with ragweed pollen.¹⁶ None had nasal polyps. Fourteen had associated mild seasonal asthma.

Preliminary assessment included determination of the level of allergy by duplicate prick skin-testing with serial 10-fold dilutions of ragweed pollen extract (1/10 to 1/10⁶) and determination of serum concentration of ragweed-specific IgE by the radioallergosorbent test (RAST) with whole-pollen extract of common ragweed (Pharmacia). Total blood eosinophil count (TEC), history of remote or recent ragweed allergen injection therapy, estimation of daily pollen exposure, age and sex of the patients were also recorded. From these data an independent observer formed two matched groups; group 1 received BDA and group 2 received placebo aerosol (Table I).

Methods

The trial began at the start of the ragweed pollen season and continued for 42 days. At the start nasal airway inspiratory resistance at a standard flow of 0.4 l/s (NAIR_{0.4}), MINF and TEC were determined. The patients

Table I—Pretrial data for patients with allergic rhinitis induced by ragweed pollen

Variable	Group 1, n = 15 (beclomethasone dipropionate therapy)	Group 2, n = 15 (placebo therapy)
Age, mean (yr)	34.2	34.1
Male (n)	8	9
Mild asthma (n)	7	7
Recent allergen injection treatment (n)	5	5
Remote allergen injection treatment (n)	4	4
Exposure, mean (h/d without air-conditioner)	15.7	15.3
Skin test end-point, mean (negative power of 10)	2.87	2.87
RAST result, mean (0 to 4)*	1.47	2.13
Total eosinophil count, mean ($\times 10^6/l$)	200	204

*Results of radioallergosorbent test: 0 = negative; 1 = borderline; 2 = clearly positive; 3 = strongly positive; 4 = very strongly positive.

From the respiratory unit, St. Joseph's Hospital, and department of medicine, McMaster University, Hamilton
*Fellow of the Medical Research Council of Canada

Reprint requests to: Dr. F.E. Hargreave, Department of medicine, St. Joseph's Hospital, 50 Charlton Ave. E, Hamilton, ON L8N 1Y4

were given double-blind a nasal inhaler containing either BDA, 50 µg per spray, or an inert Freon propellant (Freon 11, trichlorofluoromethane, and Freon 12, dichlorodifluoromethane) and were instructed to use it in each nostril four times daily. They were carefully instructed to direct the spray posteriorly in the line of the nasal cavity while gently inhaling. They were permitted to use antihistamine tablets if needed but no topical decongestants. Symptoms and number of antihistamine tablets required were recorded each day and night on a diary card. NAI_{0.4} and MINF determinations were repeated weekly on the same day of the week at the same time. The nasal mucosa was examined each week. TEC determination was repeated during the week of the peak pollen count (week 4). At the end of the study the patients were asked whether they thought their symptoms were improved (greatly, moderately or slightly) or unimproved as compared with previous years.

The diary card was similar to the one used by Norman and colleagues.³ Daily and nightly sneezing, stuffy, runny nose, red itchy eyes and cough were each recorded as 0 if they had not occurred, 1 if they had lasted less than 30 minutes, 2 if they had lasted 30 minutes to 2 hours and 3 if they had lasted more than 2 hours. The cards were reviewed with the patient every week.

NAI_{0.4} was measured by the method of Taylor and Shivalkar.¹³ A tight-fitting skin diver's mask applied over the nose and eyes was connected to a pneumotachograph for measuring flow and to a pressure transducer for measuring the transnasal pressure between the mask and the mouthpiece held tightly between the teeth and lips. Flow and pressure were recorded on the y and x axes of an x-y recorder, and the NAI_{0.4} in cm H₂O/l.s was calculated from the slope of the tangent to the pressure-flow curve at a flow of 0.4 l/s. The mean of four measurements during tidal nasal breathing was determined. Measurement of NAI_{0.4} was not possible in two subjects who gagged on the mouthpiece and in one who could not keep the posterior pharynx in communication with the mouthpiece. MINF was measured during forced nasal inspiration with the patients wearing only the mask. Patients who could flare their nostrils were requested not to do so. The best of four tracings was recorded. Measurement of MINF was possible in all patients. Antihistamines were not taken for 8 hours prior to any measurement.

Statistical analysis was done with the unpaired *t*-test and the chi-square test.

Ragweed pollen counts were measured by a Hirst automatic volumetric spore trap located on the roof of McMaster University Medical Centre at a height of 11.7 m.¹⁶

Results

Patient attrition

Twenty-two patients completed the study. Of the eight dropouts three were in the BDA group and five in the placebo group. In the BDA group one patient withdrew after 3 days because of headache and was excluded from further analyses, one withdrew at week 4 because of troublesome symptoms of rhinitis and one withdrew at week 5 for reasons unrelated to the trial. All five patients who withdrew from the placebo group did so because of troublesome symptoms of rhinitis, three at week 4 and two at week 5.




FIG. 1—Mean daily values for ragweed pollen count (grains/m³), nasal symptoms (sum of day and night scores for stuffy, runny nose and sneezing; maximum, 12), eye symptoms and cough (sum of day and night scores; maximum, 6) and antihistamine consumption (no. of tablets per day). Solid curve represents mean values for beclomethasone dipropionate aerosol (BDA) group; dotted curve, those for placebo group.

Diary cards

Results of study of the diary cards are summarized in Fig. 1. Patients receiving BDA had significantly lower mean scores than those receiving placebo ($P < 0.05$) for sneezing and stuffy, runny nose at 36 days. The difference was highly significant ($P < 0.001$) on 7 consecutive days during week 4. The BDA group also had significantly less ($P < 0.05$) cough at 10 days and antihistamine tablet consumption at 17 days. There was no significant difference in eye symptoms ($P > 0.2$) between the two groups.

Self-assessment of symptoms by the patients (Table II) showed that 12 of 14 who received BDA (86%) and 2 of 15 who received placebo (13%) had a moderate to great improvement over previous ragweed pollen seasons (X^2 test; $P < 0.01$).

Objective measurements

Mean baseline values for NAI_{0.4} were 3.30 ± 2.64 ($n = 13$) for group 1 and 5.37 ± 4.77 ($n = 13$) for group 2 (not significantly different; $P > 0.1$). Values for MINF were 1.45 ± 0.44 ($n = 14$) for group 1 and 1.27 ± 0.37 ($n = 15$) for group 2 (not significantly different; $P > 0.1$). The mean percent changes from baseline values for NAI_{0.4}, MINF and TEC are shown in Fig. 2. Although NAI_{0.4} increased 113% and TEC 56% in the placebo group, compared with 5 and 6%, respectively, in the BDA group, these differences were not significant ($P > 0.05$).

Side effects

Minor side effects were reported by two patients in each group — headache in one and post-aerosol sneezing in three. Weekly examination of the nasal mucosa revealed only changes consistent with allergic rhinitis. There was no evidence of thrush-like plaques in any patient.

Discussion

This study demonstrated that BDA sprayed into the nose in a dose of 400 µg daily effectively controlled the symptoms (particularly sneezing, rhinorrhea and nasal stuffiness) of 86% of a group of patients with allergic rhinitis. Other studies show similar improvement with BDA therapy at the same daily dose (73 to 86%),^{8,9,11} be-

Table II—Patient self-assessment of symptoms after trial of aerosol therapy

Symptomatic improvement	Group 1, n = 14 (beclomethasone dipropionate therapy)	Group 2, n = 15 (placebo therapy)
Great	10	1
Moderate	2	1
Slight	1	4
None	1	9

tamethasone-17-valerate at 400 μg daily (77 to 82%),^{6,7} hydrocortisone (84%)² and dexamethasone (75%).³

To be effective when administered intranasally hydrocortisone and dexamethasone must be given in doses that cause systemic effects. Doses of dexamethasone intranasal aerosol of 960 μg ⁵ and 1600 μg ⁴ produced partial or complete adrenal suppression in 71 and 65% of patients, respectively. No adrenal suppression was demonstrated in other studies in which BDA, 200 to 1000 μg daily, was given by nasal,^{8,10} inhalation¹⁷⁻¹⁹ or oral¹⁹ routes. Similar results were shown with nasal administration of betamethasone valerate, 400 μg daily.⁸ In the present study there was no examination for systemic effects of corticosteroids. However, the failure of BDA to suppress the eye symptoms of allergic conjunctivitis is consistent with a lack of systemic effects. This contrasts with the striking relief of eye symptoms following treatment with hydrocortisone snuff.¹

Cough developed only in the patients giving histories of mild seasonal asthma. The lower cough score in the BDA group, which contained the same number of patients with asthma as the placebo group (Table I), is most likely




FIG. 2.—Mean weekly values for ragweed pollen count (grains/m³) and mean percent change from baseline values for nasal airway inspiratory resistance at a flow of 0.4 l/s (NAIR_{0.4}), maximum inspiratory nasal flow (MINF) and total blood eosinophil count (TEC). Solid and dotted curves as in Fig. 1.

Some things just don't need to be changed



Pr Synalar[®]
(fluocinolone acetonide)

A classic topical corticosteroid
The standard of effectiveness for ten years

Quality has no substitute

Available in a wide range of presentations:

Synalar Cream
Moist or weeping lesions

Synalar Ointment
Dry, scaly lesions

Synalar Solution
Intertriginous or hairy sites

Neo-Synalar Cream
Synaform
Infected dermatoses

Synalar Bi-Otic
Otitis externa

Prescribing information on request.

SYNTEX

Syntex Ltd.
Montreal, Quebec



explained by small amounts of nasally inhaled BDA reaching the lung. The median diameter of the aerosol particles is said to vary between 1 and 10 μm , which supports this possibility. Particles of less than 4.5 μm enter the lung when inhaled through the nose.²⁰ Alternatively, the lower incidence of cough could be due to suppression of nasobronchial neurologic reflexes by BDA. Such reflexes elicited by cold air in the nose have been demonstrated in animals²¹ and suggested in man.²² They have, however, not been observed following challenge with nasal allergens.²³

A beneficial effect of BDA could not be demonstrated from measurements of nasal patency, and subjective measures appeared to be more sensitive indicators of improvement. However, there are several possible explanations why the objective measurements were less sensitive. First, the wide range of values for NAIR_{0.4} and the small number of patients in each group contributed to the lack of statistical significance. Similar reasons were incriminated in a trial comparing betamethasone valerate and sodium cromoglycate²⁴ in which symptoms clearly demonstrated greater improvement with betamethasone valerate but objective measures of nasal flow failed to support this. Since nasal resistance has been shown to have a normal day-to-day variation of up to 110%,²⁵ it may be necessary in similar trials to assess the variation in baseline values for NAIR_{0.4} and to perform more measurements during the trials. Second, the complaints of sneezing and rhinorrhea are not necessarily paralleled by changes in measurements of nasal patency. Third, the ragweed pollen count was 40% lower in 1975 than in 1974 and this could account in part for the failure of NAIR_{0.4} to increase more in the placebo group. Finally, the greater use of antihistamine tablets by the placebo group may have reduced nasal obstruction.

Aerosol-induced sneezing was the main side effect. This was as common in placebo as in BDA patients and has been observed in other short-term studies.^{8,10} Nasal administration of BDA or betamethasone valerate appears not to give rise to the lesions of local candidiasis,^{7,24,26} which occur frequently in the mouth following bronchial inhalation of BDA.²⁷ There are no data on the efficacy or complications of long-term nasal administration of BDA.

We thank L.D. Pengelly, PhD for help in setting up the technique of measurement of nasal mechanics and J. Srinivasan, PhD for supplying pollen counts. We are also grateful to S.O. Pugsley, MD and J. Dolovich, MD for allowing their patients to participate in the trial, to J. Dolovich, MD and N.L. Jones, MD for reviewing the manuscript, to Amy Mac-

Arthur, BSc for coordinating pharmacy dispensing of the drugs and to Miss M. Cuff and Mrs. E. Siminoski for assistance in preparing the manuscript.

This project was supported by Glaxo Canada Limited.

References

- HERXHEIMER H, McALLEN M: Heterogeneity of hay-fever with hydrocortisone snuff. *Lancet* 1: 537, 1956
- GODFREY MP, MAUNSELL K, PEARSON RSB: Prednisolone snuff in hay-fever, a controlled trial. *Lancet* 1: 767, 1957
- NORMAN PS, WINKENWERDER WL, MURGATROYD GW, et al: Evidence for the local action of intranasal dexamethasone aerosols in the suppression of hay fever symptoms. *J Allergy* 38: 93, 1966
- MICHELIS MI, SMITH RE, HEIMLICH EM: Adrenal suppression and intranasally applied steroids. *Ann Allergy* 25: 569, 1967
- NORMAN PS, WINKENWERDER WL, AKBAYANI BF, et al: Adrenal function during the use of dexamethasone aerosols in the treatment of ragweed hay fever. *J Allergy* 40: 57, 1967
- BROSTOFF J, CZARNY D: Effect of intranasal betamethasone-17-valerate on allergic rhinitis and adrenal function. *J Allergy* 44: 77, 1969
- ARCHER GJ, THOMAS AK, HARDING SM: Intranasal betamethasone valerate in the treatment of seasonal rhinitis. *Clin Allergy* 5: 285, 1975
- MYGIND N: Local effect of intranasal betamethasone dipropionate aerosol in hay fever. *Br Med J* 4: 464, 1973
- MORROW BROWN H, STOREY G: Beclomethasone dipropionate aerosol in the treatment of seasonal asthma and hay fever. *Clin Allergy* 4: 331, 1974
- GIBSON GJ, MABERLY DJ, LAL S, et al: Double-blind cross-over trial comparing intranasal beclomethasone dipropionate and placebo in perennial rhinitis. *Br Med J* 4: 503, 1974
- MORRISON SMITH J, CLEGG RT, COOK N, et al: Intranasal beclomethasone dipropionate in allergic rhinitis. *Br Med J* 2: 255, 1975
- SOLOMON WR, McLEAN JA, COOKINGHAM C, et al: Measurement of nasal airway resistance. *J Allergy* 36: 62, 1965
- TAYLOR G, SHIVALKAR PR: Changes in nasal airways resistance on antigenic challenge in allergic rhinitis. *Clin Allergy* 1: 63, 1971
- BENSON MK: Maximal nasal inspiratory flow rate: its use in assessing the effect of pseudoephedrine in vasomotor rhinitis. *Eur J Clin Pharmacol* 3: 182, 1971
- BRIDGER GP, PROCTOR DF: Maximum nasal inspiratory flow and nasal resistance. *Ann Otol Rhinol Laryngol* 79: 481, 1970
- CHATTERJEE J, HARGREAVE FE: Atmospheric pollen and fungal spores in Hamilton in 1972 estimated by the Hirst automatic volumetric spore trap. *Can Med Assoc J* 110: 659, 1974
- MORROW BROWN H, STOREY G, GEORGE WHS: Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. *Br Med J* 1: 585, 1972
- LAL S, HARRIS DM, BHALLA KK, et al: Comparison of beclomethasone dipropionate aerosol and prednisolone in reversible airways obstruction. *Br Med J* 3: 314, 1972
- HARRIS DM, MARTIN LE, HARRISON C, et al: The effect of oral and inhaled beclomethasone dipropionate on adrenal function. *Clin Allergy* 3: 243, 1973
- PROCTOR DF: Physiology of the upper airway, in *Handbook of Physiology*, section 3, vol 1, FENN WO, RAHN H (eds), Baltimore, Williams & Wilkins, 1964, p 326
- RALL JE, GILBERT NC, TRUMP R: Certain aspects of the bronchial reflexes obtained by stimulation of the nasopharynx. *J Lab Clin Med* 30: 953, 1945
- WELLS RE, WALKER JEC, HICKLER RB: Effects of cold air on respiratory airflow resistance in patients with respiratory-tract disease. *N Engl J Med* 263: 268, 1960
- ROSENBERG GL, ROSENTHAL RR, NORMAN PS: Inhalational challenge with ragweed pollen in ragweed sensitive asthmatics. *J Allergy Clin Immunol* 55: 126, 1975
- FRANKLAND AW, WALKER SR: A comparison of intranasal betamethasone valerate and sodium cromoglycate in seasonal allergic rhinitis. *Clin Allergy* 5: 295, 1975
- SALMAN SD, PROCTOR DF, SWIFT DL, et al: Nasal resistance: description of a method and effect of temperature and humidity changes. *Ann Otol Rhinol Laryngol* 80: 736, 1971
- CHATTERJEE SS, NASSAR WY, WILSON O, et al: Intra-nasal beclomethasone dipropionate and intra-nasal sodium cromoglycate: a comparative trial. *Clin Allergy* 4: 343, 1974
- MRC Collaborative Trial: Double-blind trial comparing two dosage schedules of the beclomethasone dipropionate aerosol in the treatment of chronic bronchial asthma. *Lancet* 2: 303, 1974

Prescribing information

Beclovent®

INDICATIONS

Treatment of steroid-responsive bronchial asthma: (1) in patients who in the past have not been on steroids but the severity of their condition warrants such treatment; (2) in steroid-dependent patients to replace or reduce oral medication through gradual withdrawal of systemic steroids.

CONTRAINDICATIONS

Active or quiescent untreated pulmonary tuberculosis, or untreated fungal, bacterial and viral infections, and in children under six. Status asthmaticus, and in patients with moderate to severe bronchiectasis.

WARNINGS

In patients previously on high doses of systemic steroids, transfer to BECLOVENT Inhaler may cause withdrawal symptoms such as tiredness, aches and pains, and depression. In severe cases acute adrenal insufficiency may occur necessitating the temporary resumption of systemic steroids.

The development of pharyngeal and laryngeal candidiasis is a cause of concern because of the extent of its penetration of the respiratory tract is unknown. If candidiasis develops the treatment should be discontinued and appropriate antifungal therapy initiated.

The incidence of candidiasis can generally be held to a minimum by having patients rinse their mouth with water after each inhalation.

PRECAUTIONS

- Essential that patients be informed that BECLOVENT Inhaler is a preventive agent, must be taken at regular intervals, and is not to be used during an asthmatic attack.
- The replacement of a systemic steroid with BECLOVENT Inhaler has to be gradual and carefully supervised by the physician, the guidelines under Dosage and Administration should be followed in each case.
- Unnecessary administration of drugs during the first trimester of pregnancy is undesirable. Corticosteroids may mask some signs of infection and new infections may appear. A decreased resistance to localized infection has been observed during corticosteroid therapy. During long-term therapy, pituitary-adrenal function and hematological status should be periodically assessed.
- Fluorocarbon propellants may be hazardous if they are deliberately abused. Inhalation of high concentrations of aerosol sprays has brought about cardiovascular toxic effects and even death, especially under conditions of hypoxia. However, evidence attests to the relative safety of aerosols when used properly and with adequate ventilation.
- There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.
- Acetylsalicylic acid should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
- Patients should be advised to inform subsequent physicians of the prior use of corticosteroids.

ADVERSE REACTIONS

No major side-effects attributable to the use of recommended doses of BECLOVENT Inhaler have been reported. No systemic effects have been observed when the daily dose was below 1 mg (twenty puffs). Above this dose, reduction of plasma cortisol, indicating adrenocortical suppression, may occur. Therapeutic doses may cause the appearance of *Candida albicans* in the mouth and throat.

The replacement of systemic steroids with BECLOVENT Inhaler may unmask symptoms of allergies which were previously suppressed by the systemic drug. Conditions such as allergic rhinitis and eczema may thus become apparent during BECLOVENT therapy after the withdrawal of systemic corticosteroids.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Overdosage may cause systemic steroid effects such as adrenal insufficiency and hypercorticism. Decreasing the dose will abolish these side-effects.

DOSAGE AND ADMINISTRATION

The optimal dosage of BECLOVENT may vary widely and must be individually determined, but the total daily dose should not exceed 1 mg of beclomethasone dipropionate (20 puffs).

Adults: The usual dose is two inhalations (100 mcg) three to four times daily. If this dose is not sufficient, it can be doubled initially. As a maintenance dose, many patients do well on two inhalations daily.

Children: Insufficient information is available to warrant the safe use in children under six years of age. The average daily dose for children over six years of age is 6 mcg/kg of body weight.

IMPORTANT:

As a steroid aerosol, *Beclovent Inhaler* is for maintenance therapy. It is not intended to give immediate relief, and effectiveness depends both on regular use and proper technique of inhalation. Patients must be instructed to take the inhalations at regular intervals and not, as with bronchodilator aerosols, when they feel a need for relief of symptoms.

They should also be instructed in the correct method of use, which is to exhale completely, then place the lips tightly around the mouthpiece. The aerosol should be actuated as the patient breathes in deeply and slowly. This ensures maximum penetration into the lungs, and the breath should be held as long as possible following each inhalation. The patient's attention should be drawn to the Instruction Sheet, enclosed in each *Beclovent* pack.

In the presence of excessive mucus secretion, the drug may fail to reach the bronchioles. Therefore, if an obvious response is not obtained after ten days, attempts should be made to remove the mucus with expectorants and/or with a short course of systemic corticosteroid treatment.

Careful attention must be given to patients previously treated for prolonged periods with systemic corticosteroids, when transferred to BECLOVENT. Initially BECLOVENT and the systemic steroid must be given concomitantly while the dose of the latter is gradually decreased. The usual rate of withdrawal of the systemic corticoid is the equivalent of 2.5 mg of prednisone every four days if the patient is under close observation.

If continuous supervision is not feasible, the withdrawal of the systemic steroid should be slower, approximately 2.5 mg of prednisone (or equivalent) every ten days. If withdrawal symptoms appear, the previous dose of the systemic drug should be resumed for a week before further decrease is attempted. There are some patients who cannot completely discontinue the oral corticosteroid. In these cases a minimum maintenance dose should be given in addition to BECLOVENT Inhaler.

SUPPLIED

BECLOVENT Inhaler is a metered-dose aerosol delivering 50 micrograms of beclomethasone dipropionate with each depression of the valve. There are two hundred doses in a container. Official product monograph on request.

Allen & Hanburys

A Glaxo Canada Ltd. Company
Toronto, Montreal